Edition:
United States

Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

27.23USD
10:40am EDT
Change (% chg)

$-1.06 (-3.75%)
Prev Close
$28.29
Open
$28.50
Day's High
$28.69
Day's Low
$26.74
Volume
37,560
Avg. Vol
157,515
52-wk High
$29.80
52-wk Low
$9.03

Latest Key Developments (Source: Significant Developments)

Collegium Reports Q4 Loss Per Share $0.54
Wednesday, 7 Mar 2018 04:01pm EST 

March 7 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.54.COLLEGIUM PHARMACEUTICAL - BELIEVE EXISTING CASH RESOURCES WILL FUND OPERATING EXPENSES, DEBT SERVICE AND CAPEX REQUIREMENTS INTO 2020.  Full Article

Collegium Filed Patent Infringement Lawsuit Against Teva Pharma USA
Thursday, 22 Feb 2018 04:15pm EST 

Feb 22 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM PHARMA SAYS FILED PATENT INFRINGEMENT LAWSUIT IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE AGAINST TEVA PHARMACEUTICALS USA INC.COLLEGIUM PHARMA SAYS LAWSUIT WAS FILED IN RESPONSE TO A PARAGRAPH IV CERTIFICATION CO RECEIVED FROM TEVA - SEC FILING.COLLEGIUM PHARMA SAYS CERTIFICATION STATED TEVA SUBMITTED ANDA TO U.S. FDA FOR GENERIC VERSION OF XTAMPZA ER (OXYCODONE) EXTENDED-RELEASE CAPSULES.  Full Article

Janus Henderson Group Reports 10.1 Pct Passive Stake In Collegium Pharmaceutical
Thursday, 11 Jan 2018 10:44am EST 

Jan 11 (Reuters) - Collegium Pharmaceutical Inc ::JANUS HENDERSON GROUP PLC REPORTS 10.1 PERCENT PASSIVE STAKE IN COLLEGIUM PHARMACEUTICAL AS OF DEC 31, 2017 - SEC FILING.  Full Article

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Thursday, 14 Dec 2017 04:30pm EST 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Collegium reports third quarter loss of $0.45 per share
Wednesday, 8 Nov 2017 04:01pm EST 

Nov 8 (Reuters) - Collegium Pharmaceutical Inc :Collegium reports third quarter financial results and provides corporate update.Q3 loss per share $0.45.Q3 earnings per share view $-0.74 -- Thomson Reuters I/B/E/S.  Full Article

Collegium receives FDA approval for sNDA for Xtampza® ER
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Collegium Pharmaceutical Inc :Collegium receives FDA approval for sNDA for Xtampza® ER.  Full Article

Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza ER
Monday, 6 Nov 2017 08:45am EST 

Nov 6 (Reuters) - Collegium Pharmaceutical Inc :Collegium notified that the FDA will not meet PDUFA goal date for SNDA for Xtampza® ER.Collegium Pharmaceutical - ‍FDA hasn't requested any additional scientific information or data regarding co's snda for Xtampza ER​.  Full Article

Collegium reports Q2 loss per share $0.72
Wednesday, 9 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Collegium Pharmaceutical Inc -:Collegium reports second quarter financial results and provides corporate update.Q2 loss per share $0.72.Q2 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Collegium-‍believe existing cash, expected cash from commercialization of xtampza er will fund operating expenses,debt service,capex requirements into 2019​.  Full Article

BRIEF-Collegium Reports Q1 Loss Per Share $0.57

* COLLEGIUM REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE